The Danish Medicines Agency has completed its review of an application for general reimbursement for Efient®. The product has been granted general reimbursement.
Efient®, co-administered with acetylsalicylic acid, is authorised for the prevention of atherothrombotic events (e.g. blood clots) in adult patients with acute coronary syndrome (e.g. blood clot in the heart) who undergo percutaneous coronary intervention (PCI).
When we compare Efient® with ticagrelor therapy, we find that the medicine fulfils the eligibility criteria for general reimbursement.
The reimbursement status of Efient® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines.
Please find the Reimbursement Committee recommendation and the Danish Medicines Agency's decision in the box to the right (in Danish only).